Choosing CRISPR-based screens in cancer

Nature features critical commentary on CRISPR from Taconic Biosciences' Dr. John Couse:

"Many possibilities for parsing cancer emerge when labs combine gene editing and screens. And RNAi retains its spot in the menu of options."
Read* the complete article at: Nature.com
*Registration required to view complete article